Randomized Trial to Evaluate Tandospirone in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GATE Study

American Journal of Ophthalmology

Volumn 160, Issue 6, 2015, Pages 1226-1234

  Jaffe, Glenn J ^a   Schmitz Valckenberg, Steffen ^b   Boyer, David ^c,d   Heier, Jeffrey ^e   Wolf Schnurrbusch, Ute ^f   Staurenghi, Giovanni ^g   Schmidt Erfurth, Ursula ^h   Holz, Frank G ^b  

^a DUKE UNIVERSITY EYE CENTER   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c RVAMG   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY OF MILAN   (Italy)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

TANDOSPIRONE; EYE DROPS; ISOINDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN AGONIST;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; AUTOFLUORESCENCE IMAGING; BLEPHARITIS; BLURRED VISION; CATARACT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EYE IRRITATION; EYE PAIN; FEMALE; FOLLOW UP; GEOGRAPHIC ATROPHY; GROWTH RATE; HUMAN; LACRIMATION DISORDER; MACULAR DEGENERATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBRETINAL NEOVASCULARIZATION; TOPICAL TREATMENT; VISUAL DISORDER; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; TREATMENT OUTCOME;

AGED; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; GEOGRAPHIC ATROPHY; HUMANS; ISOINDOLES; MACULAR DEGENERATION; MALE; OPHTHALMIC SOLUTIONS; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME;

EID: 84960994219     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2015.08.024     Document Type: Article

References (30)

1. R. Klein, S.M. Meuer, M.D. Knudtson, and B.E. Klein The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study Am J Ophthalmol 146 5 2008 692 699
2. J.S. Sunness, J. Gonzalez-Baron, C.A. Applegate, and et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration Ophthalmology 106 9 1999 1768 1779
3. F.G. Holz, E.C. Strauss, S. Schmitz-Valckenberg, and M. van Lookeren Campagne Geographic atrophy: clinical features and potential therapeutic approaches Ophthalmology 121 5 2014 1079 1091
4. A.R. Rudnicka, Z. Jarrar, R. Wormald, D.G. Cook, A. Fletcher, and C.G. Owen Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis Ophthalmology 119 3 2012 571 580
5. T.E. Clemons, R.C. Milton, R. Klein, J.M. Seddon, F.L. Ferris 3rd Age-Related Eye Disease Study Research Group Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19 Ophthalmology 112 4 2005 533 539
6. M.A. Zarbin, and P.J. Rosenfeld Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives Retina 30 9 2010 1350 1367
7. H. Lindekleiv, and M.G. Erke Projected prevalence of age-related macular degeneration in Scandinavia 2012-2040 Acta Ophthalmol 91 4 2013 307 311
8. M. van Lookeren Campagne, J. LeCouter, B.L. Yaspan, and W. Ye Mechanisms of age-related macular degeneration and therapeutic opportunities J Pathol 232 2 2014 151 164
9. J.W. Crabb, M. Miyagi, X. Gu, and et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration Proc Natl Acad Sci U S A 99 23 2002 14682 14687
10. X. Gu, S.G. Meer, M. Miyagi, and et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration J Biol Chem 278 43 2003 42027 42035
11. J.K. Shen, A. Dong, S.F. Hackett, W.R. Bell, W.R. Green, and P.A. Campochiaro Oxidative damage in age-related macular degeneration Histol Histopathol 22 12 2007 1301 1308
12. S. Beatty, H. Koh, M. Phil, D. Henson, and M. Boulton The role of oxidative stress in the pathogenesis of age-related macular degeneration Surv Ophthalmol 45 2 2000 115 134
13. B.S. Winkler, M.E. Boulton, J.D. Gottsch, and P. Sternberg Oxidative damage and age-related macular degeneration Mol Vis 5 1999 32
14. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 Arch Ophthalmol 119 10 2001 1417 1436
15. J.E. Grunwald, M. Pistilli, G.S. Ying, and et al. Growth of geographic atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology 122 4 2015 809 816
16. R.J. Collier, Y. Patel, E.A. Martin, and et al. Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress Invest Ophthalmol Vis Sci 52 5 2011 2118 2126
17. P. Thampi, H.V. Rao, S.K. Mitter, and et al. The 5HT1a receptor agonist 8-Oh DPAT induces protection from lipofuscin accumulation and oxidative stress in the retinal pigment epithelium PLoS One 7 4 2012 e34468
18. A.E. Kline, J. Yu, J.L. Massucci, R.D. Zafonte, and C.E. Dixon Protective effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin against traumatic brain injury-induced cognitive deficits and neuropathology in adult male rats Neurosci Lett 333 3 2002 179 182
19. F. Mauler, and E. Horvath Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury J Cereb Blood Flow Metab 25 4 2005 451 459
20. B.J. Oosterink, S.M. Korte, C. Nyakas, J. Korf, and P.G. Luiten Neuroprotection against N-methyl-D-aspartate-induced excitotoxicity in rat magnocellular nucleus basalis by the 5-HT1A receptor agonist 8-OH-DPAT Eur J Pharmacol 358 2 1998 147 152
21. K.M. Bode-Greuel, J. Klisch, E. Horvath, T. Glaser, and J. Traber Effects of 5-hydroxytryptamine1A-receptor agonists on hippocampal damage after transient forebrain ischemia in the Mongolian gerbil Stroke 21 12 Suppl 1990 IV164 IV166
22. K. Kamei, N. Maeda, R. Ogino, and et al. New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects Bioorg Med Chem Lett 11 4 2001 595 598
23. J.H. Prehn, C. Backhauss, C. Karkoutly, and et al. Neuroprotective properties of 5-HT1A receptor agonists in rodent models of focal and global cerebral ischemia Eur J Pharmacol 203 2 1991 213 222
24. S. Schmitz-Valckenberg, C.K. Brinkmann, F. Alten, and et al. Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration Invest Ophthalmol Vis Sci 52 10 2011 7640 7646
25. C.A. Garcia Filho, Z. Yehoshua, G. Gregori, and et al. Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration Ophthalmic Surg Lasers Imaging Retina 45 1 2014 18 31
26. F.G. Holz, A. Bindewald-Wittich, M. Fleckenstein, and et al. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration Am J Ophthalmol 143 3 2007 463 472
27. T. Ach, C. Huisingh, G. McGwin Jr., and et al. Quantitative autofluorescence and cell density maps of the human retinal pigment epithelium Invest Ophthalmol Vis Sci 55 8 2014 4832 4841
28. C. Simader, R.G. Sayegh, A. Montuoro, and et al. A longitudinal comparison of spectral-domain optical coherence tomography and fundus autofluorescence in geographic atrophy Am J Ophthalmol 158 3 2014 557 566.e551
29. J. Ambati, and B.J. Fowler Mechanisms of age-related macular degeneration Neuron 75 1 2012 26 39
30. Z. Yehoshua, C.A. de Amorim Garcia Filho, R.P. Nunes, and et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study Ophthalmology 121 3 2014 693 701